Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study

被引：7

作者：

Budde, L. Elizabeth ^{[1
]}

Olszewski, Adam J. ^{[2
]}

Assouline, Sarit ^{[3
]}

Lossos, Izidore S. ^{[4
]}

Diefenbach, Catherine ^{[5
]}

Kamdar, Manali ^{[6
]}

Ghosh, Nilanjan ^{[7
]}

Modi, Dipenkumar ^{[8
]}

Sabry, Waleed ^{[9
]}

Naik, Seema ^{[10
]}

Mehta, Amitkumar ^{[11
]}

Nakhoda, Shazia K. ^{[12
]}

Smith, Stephen D. ^{[13
]}

Dorritie, Kathleen ^{[14
]}

Jia, Ting ^{[15
]}

Pham, Song ^{[16
]}

Huw, Ling-Yuh ^{[17
]}

Wu, Hao ^{[17
]}

To, Iris ^{[17
]}

Wei, Michael C. ^{[17
]}

Chavez, Julio C. ^{[18
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA

[3] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[6] Univ Colorado, Aurora, CO USA

[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[8] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[9] Univ Saskatchewan, Saskatoon Canc Ctr, Coll Med, Saskatoon, SK, Canada

[10] Penn State Canc Inst, Hershey, PA USA

[11] Univ Alabama Birmingham, Birmingham, AL USA

[12] Fox Chase Canc Ctr, Philadelphia, PA USA

[13] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[14] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[15] Roche China Holding Ltd, Shanghai, Peoples R China

[16] F Hoffmann Roche Ltd, Basel, Switzerland

[17] Genentech Inc, San Francisco, CA USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[41] Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
Morschhauser, Franck
Flinn, Ian
Advani, Ranjana H.
Sehn, Laurie Helen
Kolibaba, Kathryn S.
Press, Oliver W.
Salles, Gilles A.
Diefenbach, Catherine S. Magid
Tilly, Herve
Assouline, Sarit E.
Chen, Andrew Tzong-Yow
Dreyling, Martin H.
Hagenbeek, Anton
Zinzani, Pier Luigi
Cheson, Bruce D.
Yalamanchili, Sreenivasu
Lu, Dan
Chai, Akiko
Chu, Yu-Waye
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[42] POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Hirata, Jamie
Perretti, Thomas
Musick, Lisa
McMillan, Andrew K.
BLOOD, 2021, 138
[43] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[44] Clinical Efficacy of Polatuzumab Vedotin in Patients with Relapsed/Refractory Large B-Cell Lymphoma after Standard of Care Axicabtagene Ciloleucel
Strati, Paolo
Watson, Grace
Horowitz, Sandra B.
Nair, Ranjit
Rodriguez, Maria Alma
Steiner, Raphael Eric
Fayad, Luis
Westin, Jason R.
Neelapu, Sattva S.
BLOOD, 2020, 136
[45] Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
Budde, Elizabeth L.
Bartlett, Nancy L.
Giri, Pratyush
Schuster, Stephen J.
Assouline, Sarit
Yoon, Sung-Soo
Fay, Keith
Matasar, Matthew J.
Gutierrez, Norma C.
Marlton, Paula
Dreyling, Martin
Yoon, Dok Hyun
Hess, Georg
Radford, John
Wiebking, Volker
Yin, Shen
Cybulski, Eva
Turner, David C.
Huang, Huang
Zhou, Mingzhu
Penuel, Elicia
Wei, Michael C.
Sehn, Laurie H.
BLOOD, 2022, 140 : 3753 - 3755
[46] Nivolumab Combined with Brentuximab Vedotin (BV) for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (R/R PMBL): Efficacy and Safety Results from the Phase 2 CheckMate 436 Study
Zinzani, Pier Luigi
Santoro, Armando
Gritti, Guiseppe
Brice, Pauline
Barr, Paul M.
Kuruvilla, John
Cunningham, David
Kline, Justin
Johnson, Nathalie A.
Mehta-Shah, Neha A.
Manley, Thomas
Francis, Stephen
Sharma, Manish
Moskowitz, Alison J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S303 - S303
[47] SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Westin, Jason
Olszewski, Adam J.
Fogliatto, Laura
Kim, Won Seog
Shin, Ho-Jin
Jeon, Young-Woo
Norasetthada, Lalita
Pavlovsky, Astrid
Rego, Eduardo
Wu, Hao
Yin, Shen
Batlevi, Connie Lee
Pham, Song
Penuel, Elicia M.
Jing, Jing
Wei, Michael C.
Budde, Lihua Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Westin, Jason
Olszewski, Adam J.
Fogliatto, Laura Maria
Kim, Won-Seog
Shin, Ho-Jin
Wu, Hao
Yin, Shen
Pham, Song
Penuel, Elicia
Jing, Jing
Wei, Michael C.
Budde, Elizabeth L.
BLOOD, 2022, 140 : 3771 - 3772
[49] First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Zhang, Huilai
Cheng, Ying
Yang, Haiyan
Zhang, Liling
Zou, Liqun
Guo, Ye
Cao, Junning
Huang, Huiqiang
Wang, Zhao
Huang, Sha
Liang, Zhiyu
Lyu, Jiaoyan
Fang, Yiqian
Cohen, Aileen
Zhou, Keshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with Relapsed/Refractory (R/R) B-cell non-Hodgkin Lymphomas (B-NHL): updated results from a Phase I/II study
von Tresckow, B.
Budde, L. E.
Bartlett, N. L.
Giri, P.
Schuster, S. J.
Assouline, S.
Yoon, S. S.
Fay, K.
Matasar, M.
Gutierrez, N. C.
Marlton, P.
Dreyling, M.
Yoon, D. H.
Hess, G.
Radford, J.
Wiebking, V.
Yin, S.
Cybulski, E.
Turner, D. C.
Huang, H.
Zhou, M.
Penuel, E.
Wei, M. C.
Sehn, L. H.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 206 - 207

← 1 2 3 4 5 →